Historical record - last NADAC effective date: 2/20/2019
Product Information
GLYBURID-METFORMIN 1.25-250 MG is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.0466 per EA under NDC 57237002305. Its NADAC has been published 306 times since Apr 9, 2014.
FDA first approved this application on Nov 14, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
1.25; 250 mg/1; mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
57237002305
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
2/20/2019
Active Ingredients
GLYBURIDE; METFORMIN HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA077870FDA Approved
11/14/2007
TE Code
AB
On Market Since
11/14/2007
Pharmacological Classes
Price Statistics
The NADAC for GLYBURID-METFORMIN 1.25-250 MG has been published 306 times since Apr 9, 2014, and over the history we have for it it has declined 46.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0466 per EA |
|---|---|
| All-time high | $0.0908 (May 11, 2016) |
| All-time low | $0.0456 (Jan 23, 2019) |
| Median price | $0.0590 |
| Average price | $0.0625 |
| Largest weekly change | +37.5% (Jun 22, 2016) |
| Weeks tracked | 306 |
| Tracking since | Apr 9, 2014 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
-46.1%
Last surveyed Feb 12, 2020 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 28% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Glyburide and Metformin Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Biguanide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GLYBURID-METFORMIN 1.25-250 MG?
The current National Average Drug Acquisition Cost (NADAC) for GLYBURID-METFORMIN 1.25-250 MG, manufactured by Rising Pharma Holdings Inc., is $0.0466 per EA (NDC 57237002305), effective Feb 12, 2020.
How has the price of GLYBURID-METFORMIN 1.25-250 MG changed over time?
Over the history we have for it, the NADAC for GLYBURID-METFORMIN 1.25-250 MG has declined 46.1%. It has been tracked across 306 weekly CMS publications since Apr 9, 2014.
What are the highest and lowest recorded NADAC prices for GLYBURID-METFORMIN 1.25-250 MG?
Since Apr 9, 2014, the NADAC for GLYBURID-METFORMIN 1.25-250 MG has ranged from a low of $0.0456 (Jan 23, 2019) to a high of $0.0908 (May 11, 2016), with a median of $0.0590 per EA.
Are there cheaper alternatives to GLYBURID-METFORMIN 1.25-250 MG?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, GLYBURID-METFORMIN 1.25-250 MG, is $0.0335 per EA — about 28% below GLYBURID-METFORMIN 1.25-250 MG.
Who manufactures GLYBURID-METFORMIN 1.25-250 MG?
GLYBURID-METFORMIN 1.25-250 MG (NDC 57237002305) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.